Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1158/1078-0432.CCR-15-0039

http://scihub22266oqcxt.onion/10.1158/1078-0432.CCR-15-0039
suck pdf from google scholar
C6063985!6063985!26473188
unlimited free pdf from europmc26473188    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid26473188      Clin+Cancer+Res 2015 ; 21 (20): 4527-35
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Advancing Clinical Trials to Streamline Drug Development #MMPMID26473188
  • Bates SE; Berry DA; Balasubramaniam S; Bailey S; Rubin EH; LoRusso PM
  • Clin Cancer Res 2015[Oct]; 21 (20): 4527-35 PMID26473188show ga
  • The last decade in oncology has been marked by the identification of numerous new potential cancer targets, and even more agents designed to inhibit them. The matrix of new targets, new agents, and the companion diagnostics required to identify the right patient for the right drug has created a major challenge for the clinical trial process. This has been compounded by the addition of new immunomodulators targeting the host immune system rather than the tumor. Recognizing the need for new approaches, industry, investigators and regulators have responded to this challenge. New clinical trial designs are being evaluated to incorporate the genomic sequence data being obtained almost routinely after cancer diagnosis. New dose-finding approaches are being proposed to identify the maximum effective dose rather than the maximum tolerated dose. The FDA is involved in the drug approval process from points early in development, and has accepted registration quality data from expansion cohorts in support of drug approval. Despite progress on several fronts, many challenges remain, including the lack of predictability of preclinical data for clinical results and Phase II data for Phase III results, an infrastructure that can be an obstacle to clinical trial development and implementation, and the increasing use of contracted Clinical Research Organizations that limit a fit for purpose approach to clinical trial execution. Perhaps most challenging and important of all are the difficulties with clinical trial accrual that can prevent study completion. Both the innovations and the challenges highlight the important role of process in progress in clinical oncology.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box